Welcome to our dedicated page for Alpha Tau Medical news (Ticker: DRTSW), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical stock.
Alpha Tau Medical Ltd. develops Alpha DaRT, an alpha-radiation cancer therapy designed for localized treatment of solid tumors through intratumoral delivery of radium-224 impregnated sources. News about the company centers on clinical programs in recurrent cutaneous squamous cell carcinoma, pancreatic cancer, recurrent glioblastoma, prostate cancer, and head and neck cancer, along with presentations of study data at oncology and gastroenterology meetings.
Recurring updates also cover regulatory activity for Alpha DaRT, including FDA pre-market approval materials, Breakthrough Device Designation references, and Japanese marketing approval for unresectable locally advanced or locally recurrent head and neck cancer. Other company news addresses financial results, corporate updates, manufacturing preparation, and investor conference presentations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Alpha Tau Medical Ltd. has initiated a feasibility and safety study of its Alpha DaRT cancer therapy, treating the first patient with advanced inoperable pancreatic cancer. Conducted at Jewish General Hospital in Montreal, the study aims to recruit 30 participants with Stage II to IV pancreatic cancer. It will assess the procedure's safety and feasibility, targeting the overall response and survival rates. CEO Uzi Sofer highlighted the trial as a significant milestone in expanding Alpha DaRT's applications. The technology uses alpha radiation for targeted tumor treatment while minimizing damage to surrounding healthy tissues.
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) announced its CFO, Raphi Levy, will present at the Jefferies Radiopharma Innovation Summit on April 3, 2023, from 3:30-4:00 PM ET in New York City. This summit focuses on innovations in the radiopharmaceutical sector. Levy will also conduct one-on-one investor meetings during the event. Founded in 2016, Alpha Tau specializes in the development of the Alpha DaRT™, a novel alpha-radiation therapy aimed at treating solid tumors. The technology was initially developed by experts from Tel Aviv University.
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) reassured investors regarding Silicon Valley Bank's recent closure, stating no financial ties existed that would impact operations. The company develops Alpha DaRT™, a therapy aimed at treating solid tumors with targeted alpha radiation, designed to minimize damage to surrounding healthy tissue. Founded in 2016, Alpha Tau focuses on furthering its technology's commercialization. The release includes forward-looking statements, cautioning that actual results may differ due to various factors including the need for regulatory approval and potential funding challenges.